Hong, J. H., Stenzl, A., Szmulewitz, R. Z., Petrylak, D., Holzbeierlein, J., Villers, A., … Armstrong, A. J. (2020). Arches - the role of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (MHSPC): post hoc analyses of high and low disease volume and risk groups. In INTERNATIONAL JOURNAL OF UROLOGY (Vol. 27, pp. 102–103).

Hong, Jun Hyuk, Arnulf Stenzl, Russell Z. Szmulewitz, Daniel Petrylak, Jeffrey Holzbeierlein, Arnauld Villers, Arun Azad, et al. “Arches - the role of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (MHSPC): post hoc analyses of high and low disease volume and risk groups.” In INTERNATIONAL JOURNAL OF UROLOGY, 27:102–3, 2020.

Hong JH, Stenzl A, Szmulewitz RZ, Petrylak D, Holzbeierlein J, Villers A, et al. Arches - the role of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (MHSPC): post hoc analyses of high and low disease volume and risk groups. In: INTERNATIONAL JOURNAL OF UROLOGY. 2020. p. 102–3.

Hong, Jun Hyuk, et al. “Arches - the role of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (MHSPC): post hoc analyses of high and low disease volume and risk groups.” INTERNATIONAL JOURNAL OF UROLOGY, vol. 27, 2020, pp. 102–03.

Hong JH, Stenzl A, Szmulewitz RZ, Petrylak D, Holzbeierlein J, Villers A, Azad A, Alcaraz A, Alekseev BY, Iguchi T, Shore ND, Rosbrook B, Baron B, Haas GP, Morlock R, Ramaswamy K, Armstrong AJ. Arches - the role of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (MHSPC): post hoc analyses of high and low disease volume and risk groups. INTERNATIONAL JOURNAL OF UROLOGY. 2020. p. 102–103.